InMed to Wind Down BayMedica Operations, Faces $670k Exit Costs
InMed’s board approved winding down BayMedica’s commercial segment before June 30, 2026, incurring severance costs of $550,000 and $120,000 in additional expenditures. The company will redirect resources to its INM-901 Alzheimer’s and INM-089 macular degeneration drug programs for IND filings and initial human trials.
1. Board Approval and Wind Down Decision
On March 4, InMed’s board ratified BayMedica leadership’s decision to wind down the commercial operations business segment prior to its fiscal year end of June 30, 2026, following potential prohibitions under H.R. 5371 that could halt sales of non-intoxicating cannabinoids effective November 12, 2026.
2. Financial Impact of Exit
BayMedica expects to incur approximately $550,000 in severance costs and $120,000 in additional wind-down expenditures through June 30, 2026, with costs partially offset by ongoing product sales; unaudited pro forma financial implications were detailed in a Form 8-K filed March 6.
3. Strategic Refocus on Drug Development
After completing the BayMedica exit, InMed will focus exclusively on advancing its core pipeline, specifically moving INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration toward Investigational New Drug filings and initial human clinical trials.